申请人:Zeneca Limited
公开号:US05441949A1
公开(公告)日:1995-08-15
The present invention relates to carbapenems and provides a compound of the formula (I) ##STR1## wherein: R.sup.1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R.sup.2 is hydrogen or C.sub.1-4 alkyl; R.sup.3 is hydrogen or C.sub.1-4 alkyl; P.sup.1 is of the formula: ##STR2## and one or two of A,B,C,D,E,F,G and H, are nitrogen and the remainder are CH; and P is bonded to the nitrogen of the linking carbamoyl group by a carbon atom, in either ring, is substituted by the carboxy group on a carbon atom, in either ring, and is optionally further substituted, by up to three substitutents, on a carbon atom, in either ring; or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them are also described.
本发明涉及碳青霉烯类药物,并提供了一种具有化学式(I)的化合物
其中:R.sup.1为1-羟乙基,1-氟乙基或羟甲基;R.sup.2为氢或C.sub.1-4烷基;R.sup.3为氢或C.sub.1-4烷基;P.sup.1为以下式的一部分:并且A、B、C、D、E、F、G和H中的一个或两个为氮,其余为CH;P通过碳原子与连接的羰基基团的氮键合,在环的任一环上,均被羧基取代,或在环的任一环上,可进一步被最多三个取代基取代;或其药学上可接受的盐或体内水解酯。还描述了其制备过程,制备中间体,作为治疗剂的用途以及含有它们的药物组合物。